Citations

Showing 10 of 108104 citations.

Fontan‐associated liver disease
Hilscher, Moira , Wells, Michael , Venkatesh, Sudhakar K. , Cetta, Frank , Kamath, Patrick S. , Wells, Michael L, Venkatesh, Sudhakar K

Mayo Clinic

Hepatology | February 18, 2022 | Volume: 75 | Issue: 5 | Pages: 1300-1321

10.1002/hep.32406 | PMID 35179797 Get It

Hemodynamic Success Is an Independent Predictor of Mid-Term Survival After Transcatheter Edge-to-Edge Mitral Valve Repair
Shaer, Ahmed El, Thaden, Jeremy, Eleid, Mackram F. , Simard, Trevor, Guerrero, Mayra , Rihal, Charanjit S. , Alkhouli, Mohamad , El Shaer, Ahmed , Eleid, Mackram F , Alkhouli, Mohamad , Guerrero, Mayra E , Shaer, Ahmed El, Thaden, Jeremy, Simard, Trevor, Rihal, Charanjit S.

Mayo Clinic

Circulation: Cardiovascular Interventions | February 18, 2022 | Volume: 15 | Issue: 3 | Pages: No page available

10.1161/circinterventions.121.011542 | PMID 35176873 Get It

Imaging Biomarkers for Diagnosis and Treatment Response in Patients with Lymphedema
Maita, Karla C. , Garcia, John P. , Torres‐Guzman, Ricardo A. , Ávila, Francisco R. , Kaplan, Jamie L. , Lu, Xiaona , Manrique, Oscar J. , Ciudad, Pedro , Forte, Antonio J. , Maita, Karla , Torres, Ricardo A , Forte, Antonio Jorge , Avila, Francisco R , Garcia, John P

Mayo Clinic

Biomarkers in Medicine | February 18, 2022 | Volume: 16 | Issue: 4 | Pages: 303-316

10.2217/bmm-2021-0487 | PMID 35176878 Get It

Social risk factors predicting outcomes of cervical myelopathy surgery
Rethorn, Zachary D., Cook, Chad E., Park, Christine, Somers, Tamara, Mummaneni, Praveen V., Chan, Andrew K., Pennicooke, Brenton H., Bisson, Erica F., Asher, Anthony L., Buchholz, Avery L., Bydon, Mohamad, Alvi, Mohammed Ali, Coric, Domagoj, Foley, Kevin T., Fu, Kai-Ming, Knightly, John J., Meyer, Scott, Park, Paul, Potts, Eric A., Shaffrey, Christopher I., Shaffrey, Mark, Than, Khoi D., Tumialan, Luis, Turner, Jay D., Upadhyaya, Cheerag D., Wang, Michael Y., Gottfried, Oren, Park, Paul , Alvi, Mohammed Ali , Alvi, Mohammed Ali , Rethorn, Zachary D., Cook, Chad E., Park, Christine, Somers, Tamara, Mummaneni, Praveen V., Chan, Andrew K., Pennicooke, Brenton H., Bisson, Erica F., Asher, Anthony L., Buchholz, Avery L., Bydon, Mohamad, Alvi, Mohammed Ali, Coric, Domagoj, Foley, Kevin T., Fu, Kai-Ming, Knightly, John J., Meyer, Scott, Park, Paul, Potts, Eric A., Shaffrey, Christopher I., Shaffrey, Mark, Than, Khoi D., Tumialan, Luis, Turner, Jay D., Upadhyaya, Cheerag D., Wang, Michael Y., Gottfried, Oren, Turner, Jay D.

Mayo Clinic

Journal of Neurosurgery: Spine | February 18, 2022 | Volume: 37 | Issue: 1 | Pages: 41-48

10.3171/2021.12.spine21874 | PMID 35090132 Get It

OBJECTIVE Combinations of certain social risk factors of race, sex, education, socioeconomic status (SES), insurance, education, employment, and one’s housing situation have been associated with poorer pain and disability outcomes after lumbar spine surgery. To date, an exploration of such factors in patients with cervical spine surgery has not been conducted. The objective of the current work was to 1) define the social risk phenotypes of individuals who have undergone cervical spine surgery for myelopathy and 2) analyze their predictive capacity toward disability, pain, quality of life, and patient satisfaction–based outcomes. METHODS The Cervical Myelopathy Quality Outcomes Database was queried for the period from January 2016 to December 2018. Race/ethnicity, educational attainment, SES, insurance payer, and employment status were modeled into unique social phenotypes using latent class analyses. Proportions of social groups were analyzed for demonstrating a minimal clinically important difference (MCID) of 30% from baseline for disability, neck and arm pain, quality of life, and patient satisfaction at the 3-month and 1-year follow-ups. RESULTS A total of 730 individuals who had undergone cervical myelopathy surgery were included in the final cohort. Latent class analysis identified 2 subgroups: 1) high risk (non-White race and ethnicity, lower educational attainment, not working, poor insurance, and predominantly lower SES), n = 268, 36.7% (class 1); and 2) low risk (White, employed with good insurance, and higher education and SES), n = 462, 63.3% (class 2). For both 3-month and 1-year outcomes, the high-risk group (class 1) had decreased odds (all p < 0.05) of attaining an MCID score in disability, neck/arm pain, and health-related quality of life. Being in the low-risk group (class 2) resulted in an increased odds of attaining an MCID score in disability, neck/arm pain, and health-related quality of life. Neither group had increased or decreased odds of being satisfied with surgery. CONCLUSIONS Although 2 groups underwent similar surgical approaches, the social phenotype involving non-White race/ethnicity, poor insurance, lower SES, and poor employment did not meet MCIDs for a variety of outcome measures. This finding should prompt surgeons to proactively incorporate socially conscience care pathways within healthcare systems, as well as to optimize community-based resources to improve outcomes and personalize care for populations at social risk.
AAPM task group report 302: Surface‐guided radiotherapy
Al‐Hallaq, Hania , Gutiérrez, Alonso N. , Havnen‐Smith, Amanda, Higgins, Susan A., Kügele, M. , Padilla, Laura , Pawlicki, Todd , Remmes, Nicholas B. , Smith, Koren, Tomé, Wolfgang A. , Havnen-Smith, Amanda, Remmes, Nicholas, Cerviño, Laura , Tang, Xiaoli

Mayo Clinic

Medical Physics | February 18, 2022 | Volume: 49 | Issue: 4 | Pages: No page available

10.1002/mp.15532 | PMID 35179229 Get It

Abstract The clinical use of surface imaging has increased dramatically, with demonstrated utility for initial patient positioning, real‐time motion monitoring, and beam gating in a variety of anatomical sites. The Therapy Physics Subcommittee and the Imaging for Treatment Verification Working Group of the American Association of Physicists in Medicine commissioned Task Group 302 to review the current clinical uses of surface imaging and emerging clinical applications. The specific charge of this task group was to provide technical guidelines for clinical indications of use for general positioning, breast deep‐inspiration breath hold treatment, and frameless stereotactic radiosurgery. Additionally, the task group was charged with providing commissioning and on‐going quality assurance (QA) requirements for surface‐guided radiation therapy (SGRT) as part of a comprehensive QA program including risk assessment. Workflow considerations for other anatomic sites and for computed tomography simulation, including motion management, are also discussed. Finally, developing clinical applications, such as stereotactic body radiotherapy (SBRT) or proton radiotherapy, are presented. The recommendations made in this report, which are summarized at the end of the report, are applicable to all video‐based SGRT systems available at the time of writing.
Predicting malignant pleural effusion during diagnostic pleuroscopy with biopsy: A prospective multicentre study
Grosu, Horiana B. , Kern, Ryan , Maldonado, Fabien , Casal, Roberto F. , Eapen, Georgie A. , Ost, David E. , Jiménez, Carlos , Frangopoulos, Frangiskos, Sabath, Bruce F. , Vakil, Erik , Schwalk, Audra, Marcoux, Mathieu , Sagar, Ala-Eddin S. , Nasim, Faria, Lin, Julie , Salahudin, Moiz, Arain, Hasan Muhammad, Noor, Laila , Montanez, Diana, Stewart, John , Mullon, John J., Porfyridis, Ilias, Casal, Roberto , Ost, David E , Vakil, Erik , Salahudin, Moiz , Mullon, John, Kern, R , Andersen, Clark R. , Li, Liang , Jimenez, Carlos, Michael, Michalis

Mayo Clinic

Respirology | February 18, 2022 | Volume: 27 | Issue: 5 | Pages: 350-356

10.1111/resp.14232 | PMID 35178828 Get It

AbstractBackground and objectivePleuroscopy with pleural biopsy has a high sensitivity for malignant pleural effusion (MPE). Because MPEs tend to recur, concurrent diagnosis and treatment of MPE during pleuroscopy is desired. However, proceeding directly to treatment at the time of pleuroscopy requires confidence in the on‐site diagnosis. The study's primary objective was to create a predictive model to estimate the probability of MPE during pleuroscopy.MethodsA prospective observational multicentre cohort study of consecutive patients undergoing pleuroscopy was conducted. We used a logistic regression model to evaluate the probability of MPE with relation to visual assessment, rapid on‐site evaluation (ROSE) of touch preparation and presence of pleural nodules/masses on computed tomography (CT). To assess the model's prediction accuracy, a bootstrapped training/testing approach was utilized to estimate the cross‐validated area under the receiver operating characteristic curve.ResultsOf the 201 patients included in the study, 103 had MPE. Logistic regression showed that higher level of malignancy on visual assessment is associated with higher odds of MPE (OR = 34.68, 95% CI = 9.17–131.14,p < 0.001). The logistic regression also showed that higher level of malignancy on ROSE of touch preparation is associated with higher odds of MPE (OR = 11.63, 95% CI = 3.85–35.16,p < 0.001). Presence of pleural nodules/masses on CT is associated with higher odds of MPE (OR = 6.61, 95% CI = 1.97–22.1,p = 0.002). A multivariable logistic regression model of final pathologic status with relation to visual assessment, ROSE of touch preparation and presence of pleural nodules/masses on CT had a cross‐validated AUC of 0.94 (95% CI = 0.91–0.97).ConclusionA prediction model using visual assessment, ROSE of touch preparation and CT scan findings demonstrated excellent predictive accuracy for MPE. Further validation studies are needed to confirm our findings.
Dynamic risk profiling of HCC recurrence after curative intent liver resection
Ivanics, Tommy , Perez, Carla , Claasen, Marco P. A. W. , Patel, Madhukar S. , Morgenshtern, Gabriela , Erdman, Lauren , Shwaartz, Chaya , Rajendran, Luckshi , O’Kane, Grainne M. , Murillo Perez, Carla Fiorella , Hansen, Bettina E. , Cleary, Sean P , Sapisochin, Gonzalo , Ivanics, Tommy , Cleary, Sean P. , Sapisochín, Gonzalo , Patel, Madhukar , O'Kane, Grainne M.

Mayo Clinic

Hepatology | February 18, 2022 | Volume: 76 | Issue: 5 | Pages: 1291-1301

10.1002/hep.32411 | PMID 35178739 Get It

Abstract Background and Aims Following liver resection (LR) for HCC, the likelihood of survival is dynamic, in that multiple recurrences and/or metastases are possible, each having variable impacts on outcomes. We sought to evaluate the natural progression, pattern, and timing of various disease states after LR for HCC using multistate modeling and to create a practical calculator to provide prognostic information for patients and clinicians. Approach and Results Adult patients undergoing LR for HCC between January 2000 and December 2018 were retrospectively identified at a single center. Multistate analysis modeled post‐LR tumor progression by describing transitions between distinct disease states. In this model, the states included surgery, intrahepatic recurrence (first, second, third, fourth, fifth), distant metastasis with or without intrahepatic recurrence, and death. Of the 486 patients included, 169 (34.8%) remained recurrence‐free, 205 (42.2%) developed intrahepatic recurrence, 80 (16.5%) developed distant metastasis, and 32 (7%) died. For an average patient having undergone LR, there was a 33.1% chance of remaining disease‐free, a 31.0% chance of at least one intrahepatic recurrence, a 16.3% chance of distant metastasis, and a 19.8% chance of death within the first 60 months post‐LR. The transition probability from surgery to first intrahepatic recurrence, without a subsequent state transition, increased from 3% (3 months) to 17.4% (30 months) and 17.2% (60 months). Factors that could modify these probabilities included tumor size, satellite lesions, and microvascular invasion. The online multistate model calculator can be found on https://multistatehcc.shinyapps.io/home/. Conclusions In contrast to standard single time‐to‐event estimates, multistate modeling provides more realistic prognostication of outcomes after LR for HCC by taking into account many postoperative disease states and transitions between them. Our multistate modeling calculator can provide meaningful data to guide the management of patients undergoing postoperative surveillance and therapy.
Surgical Experience and Management of Intracranial Neurenteric Cysts: Single-Center Experience and Review of the Literature
Yagnik, Karan J. , Vakharia, Kunal , Vizcaíno, M. Adelita , Link, Michael J., Gompel, Jamie J. Van , Benson, John C. , Van Gompel, Jamie J , Vaubel, Rachael A. , Daniels, David J. , Link, Michael J.

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 18, 2022 | Volume: 84 | Issue: 03 | Pages: 272-280

10.1055/a-1775-0865 | PMID 37180870 Get It

Abstract Introduction Neurenteric cysts (NECs) are rare, congenital lesions lined by endodermal cell-derived columnar or cuboidal epithelium. Based on previous studies, gross total removal of the capsule has been presumed to be the ideal surgical goal. Objective This series was undertaken to further understand the risk of recurrence based on the extent of capsule resection. Methods Records were retrospectively reviewed for all patients with radiographic or pathological evidence of intracranial NEC from 1996 to 2021. Results A total of eight patients were identified; four of eight (50%) presented with headache, and four had signs of one or more cranial nerve syndromes. One patient (13%) presented with third nerve palsy, one (13%) had sixth nerve palsy, and two (25%) with hemifacial spasm. One patient (13%) presented with signs of obstructive hydrocephalus. Magnetic resonance imaging demonstrated T2 hyper- or isointense lesions. Diffusion-weighted imaging was negative in all patients (100%) and T1 contrast-enhanced imaging demonstrated minimal rim enhancement in two patients (25%). In three of eight (38%), a gross total resection (GTR) was achieved, while in four (50%), a near-total resection, and in one (13%), a decompression was performed. Recurrences occurred in two (25%) patients, one with decompression and another with near-total resection, among these 1/2 required repeat surgery after a mean follow-up of 77 months. Conclusion In this series, none from GTR group demonstrated recurrence, while 40% of those receiving less than GTR recurred, underpinning the importance of maximally safe resection in these patients. Overall patients did well without major morbidity from surgery.
Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion
Chakravarty, Debyani , Johnson, Amber , Sklar, Jeffrey, Lindeman, Neal I., Moore, Kathleen N. , Ganesan, Shridar , Lovly, Christine M. , Perlmutter, Jane, Gray, Stacy W. , Hwang, Jimmy, Azad, Nilofer S. , Tafe, Laura, Tafe, Laura J. , Moore, Kathleen , Lieu, Christopher , André, Fabrice , Azad, Nilofer , Borad, Mitesh J , Messersmith, Hans , Robson, Mark , Meric-Bernstam, Funda , Gray, Stacy W , Chakravarty, Debyani , Johnson, Amber , Sklar, Jeffrey, Lindeman, Neal I., Ganesan, Shridar , Lovly, Christine Marie , Perlmutter, Jane, Hwang, Jimmy

Mayo Clinic

Journal of Clinical Oncology | February 17, 2022 | Volume: 40 | Issue: 11 | Pages: 1231-1258

10.1200/jco.21.02767 | PMID 35175857 Get It

PURPOSEAn ASCO provisional clinical opinion offers timely clinical direction to ASCO's membership following publication or presentation of potentially practice-changing data from major studies. This provisional clinical opinion addresses the appropriate use of tumor genomic testing in patients with metastatic or advanced solid tumors.CLINICAL CONTEXTAn increasing number of therapies are approved to treat cancers harboring specific genomic biomarkers. However, there is a lack of clarity as to when tumor genomic sequencing should be ordered, what type of assays should be performed, and how to interpret the results for treatment selection.PROVISIONAL CLINICAL OPINIONPatients with metastatic or advanced cancer should undergo genomic sequencing in a certified laboratory if the presence of one or more specific genomic alterations has regulatory approval as biomarkers to guide the use of or exclusion from certain treatments for their disease. Multigene panel–based assays should be used if more than one biomarker-linked therapy is approved for the patient's disease. Site-agnostic approvals for any cancer with a high tumor mutation burden, mismatch repair deficiency, or neurotrophic tyrosine receptor kinase ( NTRK) fusions provide a rationale for genomic testing for all solid tumors. Multigene testing may also assist in treatment selection by identifying additional targets when there are few or no genotype-based therapy approvals for the patient's disease. For treatment planning, the clinician should consider the functional impact of the targeted alteration and expected efficacy of genomic biomarker–linked options relative to other approved or investigational treatments. Additional information is available at www.asco.org/assays-and-predictive-markers-guidelines .
Refined Capsid Structure of Human Adenovirus D26 at 3.4 Å Resolution
Reddy, Vijay , Yu, Xiaodi , Barry, Michael A. , Reddy, Vijay S , Barry, Michael A

Mayo Clinic

Viruses | February 17, 2022 | Volume: 14 | Issue: 2 | Pages: 414

10.3390/v14020414 | PMID 35216007 Get It

Various adenoviruses are being used as viral vectors for the generation of vaccines against chronic and emerging diseases (e.g., AIDS, COVID-19). Here, we report the improved capsid structure for one of these vectors, human adenovirus D26 (HAdV-D26), at 3.4 Å resolution, by reprocessing the previous cryo-electron microscopy dataset and obtaining a refined model. In addition to overall improvements in the model, the highlights of the structure include (1) locating a segment of the processed peptide of VIII that was previously believed to be released from the mature virions, (2) reorientation of the helical appendage domain (APD) of IIIa situated underneath the vertex region relative to its counterpart observed in the cleavage defective (ts1) mutant of HAdV-C5 that resulted in the loss of interactions between the APD and hexon bases, and (3) the revised conformation of the cleaved N-terminal segments of pre-protein VI (pVIn), located in the hexon cavities, is highly conserved, with notable stacking interactions between the conserved His13 and Phe18 residues. Taken together, the improved model of HAdV-D26 capsid provides a better understanding of protein–protein interactions in HAdV capsids and facilitates the efforts to modify and/or design adenoviral vectors with altered properties. Last but not least, we provide some insights into clotting factors (e.g., FX and PF4) binding to AdV vectors.